Supplementary appendix
|
|
- Clement Dennis
- 6 years ago
- Views:
Transcription
1 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; published online March S (15)
2 Novel Glycaemic Treatment Strategies and Cardiovascular Outcomes in Patients with or at Risk for Diabetes: A Meta-Analysis of Randomised Trials Supplementary Appendix 1
3 Search Strategies for MEDLINE Database: Ovid MEDLINE(R) <1946 to February 20 (Week 3) 2015> Search Strategy: 1 risk.mp. ( ) 2 exp Heart Failure/ (88948) 3 exp heart failure/ or heart failure.mp. (134704) 4 exp Cardiomyopathy, Dilated/ (13211) 5 exp Cardiomyopathy, Dilated/ or Cardiomyopathy.mp. (52586) 6 exp cardiovascular disease/ or cardiovascular disease.mp. ( ) 7 exp Diabetes Mellitus/ (320069) 8 exp Hemoglobin A, Glycosylated/ (23403) 9 exp Blood Glucose/ (130757) 10 (diabetes mellitus or type 2 or haemoglobin A1c or glycosylated or glycated or glucose).mp. (690811) 11 (glycemic control or glucose control or aggressive or intensive or tight).mp. (332393) 12 2 or 3 or 4 or 5 or 6 ( ) 13 7 or 8 or 9 or 10 or 11 ( ) 14 1 and 12 and 13 (65999) 15 limit 14 to randomized controlled trial (3899) 2
4 Appendix Figure 1. Funnel plot for heart failure stratified by anti-diabetic drug class/strategy. The outer dashed lines indicate the triangular confidence interval boundary within which 95% of studies are expected to lie in the absence of bias or heterogeneity. The dashed vertical line represents the summary treatment effect point estimate. A relative risk (RR) value of 1 represents the null treatment effect point estimate. 3
5 Appendix Figure 2. Funnel plot for MACE stratified by anti-diabetic drug class/strategy. The outer dashed lines indicate the triangular confidence interval boundary within which 95% of studies are expected to lie in the absence of bias or heterogeneity. The dashed vertical line represents the summary treatment effect point estimate. A relative risk (RR) value of 1 represents the null treatment effect point estimate. 4
6 Appendix Table 1. Definition of Heart Failure (HF) and Major Adverse Cardiovascular Events (MACE) Trial HF Definition MACE Definition Expanded MACE Definition UKPDS 33 (1998) 1 HF (not associated with MI), by clinical symptoms confirmed by Kerley B lines, rales, raised jugular venous pressure, or third heart sound Fatal and non-fatal MI Any diabetes-related endpoint (sudden death, glycaemic death, fatal or non-fatal MI, UA, HF, stroke, renal failure, amputation of at least one digit, vitreous hemorrhage, retinal photocoagulation, blindness in one eye, or cataract extraction) PROactive (2005) 2-4 HF not needing or needing hospitalization or prolonged a hospitalization stay, was fatal or life threatening, or resulted in persistent significant disability or incapacity Death, MI, or stroke Death, non-fatal MI (including silent MI), stroke, UA, coronary revascularization, peripheral artery revascularization, or limb amputation above the ankle ADOPT (2006) 5 Investigator-reported congestive HF Fatal and non-fatal MI Any fatal or non-fatal CV event (MI, CHD, stroke, HF, PAD) DREAM (2006) 6 Acute treatment for HF with at least two of the following criteria: typical signs and symptoms, typical radiological evidence, use of diuretics, vasodilators, or inotropes CV death, MI, or stroke CV death, MI, stroke, HF, arterial revascularization procedures, new angina with objective evidence of ischemia, or ventricular arrhythmia needing resuscitation ACCORD (2008) 7 Fatal HF or non-fatal hospitalization for congestive HF CV death, MI, or stroke NR ADVANCE (2008) 8 Investigator-reported congestive HF CV death, MI, or stroke Any fatal or non-fatal CV event (MI, CHD, stroke, HF) BARI2D (2009) 9 The occurrence of 1 or more of dyspnea on exertion, Death, MI, or stroke NR bilateral pedal edema, fatigue, orthopnea, and paroxysmal nocturnal dyspnea RECORD (2009) 10 Fatal HF and non-fatal HF hospitalization CV death, MI, or stroke CV death, MI, stroke, HF, or UA VADT (2009) 11 New or worsening congestive HF Fatal and non-fatal MI CV death, MI, stroke, new or worsening HF, arterial revascularization surgery, inoperable CHD, or amputation for ischemic gangrene ORIGIN (2012) 12 Hospitalization for congestive HF (new or recurrent) CV death, MI, or stroke CV death, MI, stroke, hospitalization for HF, or arterial revascularization EXAMINE (2013) 13, 14 Hospitalization for HF (new or recurrent) CV death, MI, or stroke Death, MI, stroke, hospitalization for HF, or urgent coronary revascularization for UA Look-AHEAD (2013) 15 Hospitalized congestive HF (new onset or worsened) CV death, MI, or stroke CV death, MI, stroke, or hospitalization for UA SAVOR-TIMI 53 (2013) 16 HF requiring hospitalization CV death, MI, or ischemic stroke CV death, MI, ischemic stroke, hospitalization for HF, coronary revascularization, or UA AleCardio (2014) 17 HF requiring hospitalization CV death, MI, or stroke CV death, MI, stroke, or hospitalization for UA Abbreviations: CHD: coronary heart disease; CV: cardiovascular; HF: heart failure; MI: myocardial infarction; NR: not reported; PAD: peripheral artery disease; UA: unstable angina. 5
7 Appendix Table 2. Trial Quality Metrics and Risk of Bias Trial Blinding Discontinued Drug/Strategy* (%) Lost to Follow Up (%) Withdrawn Consent (%) Cardiovascular Endpoint Adjudication by Blinded Central Committee UKPDS 33 (1998) 1 Open label NR 2.0% NR Two independent physicians assigned ICD-9 codes PROactive (2005) 2-4 Double blind 16.5% 0.04% 6.0% Primary and secondary endpoints, HF in retrospect ADOPT (2006) 5 Double blind 39.6% 5.4% 7.5% No. Retrospective adjudication of HF SAEs by 2 independent cardiologists DREAM (2006) 6 Double blind 23.2% 0.7% 1.3% Yes ACCORD (2008) 7 Open label 6.8% 0.49% 0% Yes ADVANCE (2008) 8 Open label 24.4% 0.15% NR Primary endpoint only, not HF BARI2D (2009) 9 Open label 1.8% 2.8% 2.4% Stroke and cause of death only, not HF RECORD (2009) 10 Open label 12% 2.8% 8.9% Yes VADT (2009) 11 Open label 14.5% 6.4% 6.1% Yes ORIGIN (2012) 12 Open label 19% 0.75% 0.2% Yes EXAMINE (2013) 13 Double blind 21.7% 0.5% NR Yes Look-AHEAD (2013) 15 Open label NR 3.7% NR Yes SAVOR-TIMI 53 (2013) 16 Double blind 19.6% 0.17% 2.4% Yes AleCardio (2014) 17 Double blind 27.3% 3.1% 3.2% Yes *Not mutually exclusive from lost to follow-up or withdrawn consent categorization. Abbreviations: ICD-9: international classification of diseases, 9th edition; HF: heart failure; NR: not reported; SAE: severe adverse events. 6
8 Appendix Table 3. Assessment of Publication Bias Outcome Egger s linear regression test P- value (1-sided) Heart failure MACE Expanded MACE CV death MI Stroke UA Coronary revascularization
9 Appendix Table 4. Multivariate Meta-Regression Results Meta-regression Number of obs = 12 REML estimate of between-study variance tau2 = % residual variation due to heterogeneity I-squared_res = 59.69% Proportion of between-study variance explained Adj R-squared = 46.90% Joint test for all covariates Model F(6,5) = 1.59 With Knapp-Hartung modification Prob > F = 0.31 Variable Log RR P Age Duration of follow-up Duration of diabetes Proportion with CVD Mean absolute HbA1c achieved Weight gain
10 References 1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macrovascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet. 2007; 369(9557): Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes care. 2007; 30(11): Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23): Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541): Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24): Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373(9681):
11 11. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360(2): Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4): White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14): Zannad F, Cannon C, Cushman W, Bakris G, Nissen S, Heller S, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 1-10; Published Online March 10, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369(2): Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14): Lincoff A, Tardif J, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: The alecardio randomized clinical trial. JAMA. 2014; 311(15):
Supplementary Online Content
Supplementary Online Content McGuire DK, Van de Werf F, Armstrong PW, et al; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ray K K, Seshasai S R K, Wijesuriya S,
More informationArticles. Funding None.
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials Jacob A Udell, Matthew A Cavender, Deepak
More informationDIABETES AND METABOLIC SYNDROME
TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61
More informationSupplementary Text A. Full search strategy for each of the searched databases
Supplementary Text A. Full search strategy for each of the searched databases MEDLINE: ( diabetes mellitus, type 2 [MeSH Terms] OR type 2 diabetes mellitus [All Fields]) AND ( hypoglycemia [MeSH Terms]
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationORIGINAL ARTICLE. Erland ERDMANN, 1 Robert SPANHEIMER 2 and Bernard CHARBONNEL 3 on behalf of the PROactive Study Investigators.
Journal of Diabetes 2 (2010) 212 220 ORIGINAL ARTICLE Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin angiotensin
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationArticles. concentration (HbA 1c
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Kausik K Ray, Sreenivasa Rao Kondapally Seshasai*,
More informationWhy are we doing cardiovascular outcome trials in type 2 diabetes?
MEDICAL GRAND ROUNDS VENU MENON, MD Heart and Vascular Institute, Cleveland Clinic BHUVNESH AGGARWAL, MD Heart and Vascular Institute, Cleveland Clinic TAKE-HOME POINTS FROM LECTURES BY CLEVELAND CLINIC
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationMetformin. Sulfonylurea. Thiazolidinedione. Insulin
동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationDiabetes and the Heart
Diabetes and the Heart By Samir Naim Assaad, MD, MRCP(UK), FRCP(Edin), FRCP(Lond) Professor of Medicine & Endocrinology University of Alexandria EGYPT Disclosure None, related to this presentation Road
More informationOBJECTIVE RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS. Diabetes Care Volume 39, July CARDIOVASCULAR AND METABOLIC RISK
Diabetes Care Volume 39, July 2016 1267 Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial Diabetes Care 2016;39:1267 1273 DOI: 10.2337/dc16-0303
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationThe delicate balance of disease
Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes Vani P. Sanon, MD, Saurabh Sanon, MD, Son V. Pham, MD, FACC, and Robert Chilton, DO, FACC The delicate
More informationCardiovascular disease prevention in diabetes: uncertainties and ethics
Review Ethical Perspective Diabetes Management Cardiovascular disease prevention in diabetes: uncertainties and ethics Jonathan E Shaw*,1 & Daniel Fineberg 1 / Practice points Glucose-lowering therapy
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationSupplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.
Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationS. A. Mostafa 1, R. L. Coleman 1, O. F. Agbaje 1, A. M. Gray 2, R. R. Holman 1,3 and M. A. Bethel 1. Abstract. Introduction
DIABETICMedicine Research: Complications Modelling incremental benefits on complications rates when targeting lower HbA 1c levels in people with Type 2 diabetes and cardiovascular disease S. A. Mostafa
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Shah AD, Langenberg C, Rapsomaniki E, et al.
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationShifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials
Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials Faramarz Ismail-Beigi, MD, PhD 1, Etie Moghissi, MD 2, Mikhail Kosiborod, MD 3, and
More informationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
The new england journal of medicine Original Article Effect of on Cardiovascular Outcomes in Type 2 Diabetes Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D.,
More informationThe New Diabetes Standard of Care: More Than Just Glycemic Control. Copyright
CLINICAL Viewpoint The New Diabetes Standard of Care: More Than Just Glycemic Control Advancement in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationGSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More information10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer
Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials Eckhard Leifke, MD PhD Senior Medical Director Takeda Global Research Development Center, Inc. Presentation
More informationDiabetes is very common in older people, Glycaemic control in the elderly: What should we be aiming for? Article. Andrew McGovern
Article Glycaemic control in the elderly: What should we be aiming for? Andrew McGovern Diabetes is very common in older people, who are at high risk of diabetes-related complications. Overtreatment in
More informationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Original Article Effect of on Cardiovascular Outcomes in Type 2 Diabetes Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationAn Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus
Nevada Academy of Family Physicians 29 th Annual Summer CME Meeting August 3 5, 2018 An Update on Guidelines and Evidence of the Treatment of Type 2 Diabetes Mellitus Presented by: James D. Honeycutt,
More informationStudy No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of
Study No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Diabetes and Obesity Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies Sophia
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationType 2 diabetes affects an estimated 25.8 million
Hosp Pharm 2014;49(8):697 701 2014 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj4908-697 Cardiovascular Therapeutics Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Diabetes Management Coutts S, Wein T (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2014 Heart and Stroke Foundation November 2014
More informationDiabetes Drugs and Cardiac Disease. Disclosures
Diabetes Drugs and Cardiac Disease Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Disclosures None 1 Written Comments As I have said every
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationEffective Health Care
Number 8 Effective Health Care Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes Executive Summary Background Type 2 diabetes is characterized by insulin
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationReview Article Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
Diabetes Research Volume 2016, Article ID 1643496, 7 pages http://dx.doi.org/10.1155/2016/1643496 Review Article Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS Samit
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationThiazolidinedione-Associated Congestive Heart Failure and Pulmonary Edema
Search the Journal search Advanced Search > Home Current Issue Past Issues Reprints Submissions Subscriptions Permissions About Us MAYO CLIN PROC. 2003;78:1088-1091 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION
More informationGlaxoSmithKline has reviewed the editorial by Dr. Steven Nissen published online on February 12. 1
21 February 2010 Thomas F. Lüscher, Editor-in-Chief Sam Rogers, Managing Editor Susanne B. Dedecke, Managing Editor European Heart Journal TheZurichHeartHouse Moussonstrasse 4 CH-8091 Zurich Switzerland
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationGlucose Control: Does it lower CV risk?
Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationFollow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
The new england journal of medicine Original Article Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes Rodney A. Hayward, M.D., Peter D. Reaven, M.D., Wyndy L. Wiitala, Ph.D.,
More informationALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment
More informationGabriele Perriello Dipartimento di Medicina Interna Azienda Ospedaliera-Universitaria di Perugia. Metformina, sulfoniluree, pioglitazone
Gabriele Perriello Dipartimento di Medicina Interna Azienda Ospedaliera-Universitaria di Perugia Metformina, sulfoniluree, pioglitazone Hypoglycemic therapy and CV risk Combination of SUs and Metformin
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationDiabetes at the limits
Earn 3 CPD Points online Extending the limits of diabetes care Diabetes at the limits KEY MESSAGES There is a very close relationship between the extent of hypoglycaemia and the failure of glucose lowering
More information